Germ Cell Tumor Clinical Trial
Official title:
Phase II Study of Cisplatin Plus Epirubicin Salvage Chemotherapy in Refractory Germ Cell Tumors
This study proposes to evaluate the combination of cisplatin plus epirubicin in patients with refractory germ cell tumor not amendable to cure with surgery or standard platinum salvage chemotherapy. This regimen will be used in eligible patients after progression on ECOG Study E39897.
To determine the feasibility and toxicity of combining epirubicin to fixed does cisplatin; to determine the partial and complete response rate and duration of remission; to determine the toxicity; to ascertain the potential for greater than 12 month continuous disease-free survival and, therefore, potential curability. ;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06133543 -
Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer
|
N/A | |
| Terminated |
NCT00369291 -
CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant
|
Phase 1 | |
| Recruiting |
NCT05874063 -
Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors
|
Phase 3 | |
| Completed |
NCT03194906 -
Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors
|
Phase 2 | |
| Completed |
NCT01466231 -
Everolimus in Refractory Testicular Germ Cell Cancer
|
Phase 2 | |
| Recruiting |
NCT04791228 -
A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT03418844 -
Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy
|
N/A | |
| Recruiting |
NCT05889585 -
Morbidity, Long-term Side Effects and Quality of Life in Germ-cell Tumor Long Survivors Treated With High-dose Chemotherapy and Autologous Stem Cell Transplant
|
||
| Recruiting |
NCT05394675 -
A Study of DS-9606a in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03067181 -
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
|
Phase 3 | |
| Withdrawn |
NCT03960151 -
Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy
|
Phase 2 | |
| Active, not recruiting |
NCT03158064 -
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
|
Phase 2 | |
| Completed |
NCT03950830 -
Disulfiram and Cisplatin in Refractory TGCTs.
|
Phase 2 | |
| Recruiting |
NCT00898755 -
Collecting and Storing Tissue From Young Patients With Cancer
|
||
| Recruiting |
NCT04804007 -
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
|
Phase 2 | |
| Terminated |
NCT02988843 -
Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors
|
Phase 2 | |
| Recruiting |
NCT05259605 -
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
|
||
| Active, not recruiting |
NCT03638167 -
EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
|
Phase 1 | |
| Recruiting |
NCT04308330 -
Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
|
Phase 1 | |
| Recruiting |
NCT06418789 -
High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors
|
Phase 2 |